Answers are grounded in this paper and cite their sources.
. Short stature is common, but data on endocrine function and response to recombinant human growth hormone (rhGH) are limited. We describe a female child with genetically confirmed ZTTK syndrome presenting with profound proportionate short stature, hypotonia, and developmental delay. Insulin-like growth factor 1 (IGF-1) of 91 ng/mL (Systeme international [SI]: 11.9 nmol/L; reference range, 33.6-170.5 ng/mL [SI: 4.4-22.3 nmol/L]) was normal, and peak growth hormone (GH) concentration on arginine stimulation testing was 7.2 ng/mL (SI: 21.6 mIU/L], above the UK diagnostic cutoff for GH deficiency (<6.7 ng/mL [SI: <20.1 mIU/L]). Given severely impaired linear growth and declining height velocity, a monitored trial of rhGH was initiated. Treatment with rhGH (0.035 mg/kg/day) resulted in >50% increase in height velocity from baseline (4.3-7.2 cm/year), suggesting a good response to rhGH, with sustained improvement over 2 years (height standard deviation score -4.16 to -3.40). Insulin-like growth factor 1, thyroid function, glucose, and glycated hemoglobin A1c remained normal. No adverse effects were observed. This case demonstrates a clinically significant growth response to rhGH in ZTTK syndrome despite absence of biochemical GH deficiency, supporting a supervised 12-month therapeutic trial.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: